



Universiteit
Leiden
The Netherlands

Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency

Karbiener, M.; Kindle, G.; Meyts, I.; Seppänen, M.R.J.; Candotti, F.; Kamieniak, M.; ... ; ESID-COVID Consortium

Citation

Karbiener, M., Kindle, G., Meyts, I., Seppänen, M. R. J., Candotti, F., Kamieniak, M., ... Seidel, M. G. (2024). Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency. *Journal Of Medical Virology*, 96(6). doi:10.1002/jmv.29738









Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/4213116>

Note: To cite this publication please use the final published version (if applicable).

Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency

Michael Karbiener¹  | Gerhard Kindle^{2,3}  | Isabelle Meyts^{4,5}  |
Mikko R. J. Seppänen^{6,7,8}  | Fabio Candotti⁹  | Marta Kamieniak¹⁰  |
Reinhard Ilk¹¹ | Thomas R. Kreil¹  | Markus G. Seidel^{12,13}  | ESID-COVID
Consortium

¹Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria

²Institute for Immunodeficiency, Center for Chronic Immunodeficiency, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

³Centre for Biobanking FREEZE, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

⁴Department of Pediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium

⁵Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

⁶Adult Immunodeficiency Unit, Infectious Diseases, Inflammation Center, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland

⁷ERN-RITA Core Center, RITAFIN, Helsinki, Finland

⁸Rare Disease Center and Pediatric Research Center, Children and Adolescents, University of Helsinki and HUS Helsinki University Hospital, Helsinki, Finland

⁹Division of Immunology and Allergy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

¹⁰Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA

¹¹Global Manufacturing Sciences, Takeda Manufacturing Austria AG, Vienna, Austria

¹²on behalf of the ESID Registry Working Party; Styrian Children's Cancer Research Unit for Cancer and Inborn Errors of the Blood and Immunity in Children, Medical University of Graz, Graz, Austria

¹³Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, Medical University of Graz, Graz, Austria

Correspondence

Thomas R. Kreil, Global Pathogen Safety,
Takeda Manufacturing Austria AG,
Benatzkygasse 2-6/G, 1221 Vienna, Austria.
Email: thomas.kreil@takeda.com

Funding information

Takeda Pharmaceuticals International

Abstract

Immunocompromised individuals are at significantly elevated risk for severe courses of coronavirus disease 2019 (COVID-19). In addition to vaccination, *severe acute respiratory syndrome coronavirus 2* (SARS-CoV-2) neutralizing antibodies (nAbs) have been applied throughout the pandemic, with time of treatment onset and potency against the currently prevailing virus variant identified as relevant factors for medical benefit. Using data from the European Society for Immunodeficiencies (ESID) registry, the present study evaluated COVID-19 cases in three groups of patients with inborn errors of immunity (IEI; 981 agammaglobulinemia patients on immunoglobulin replacement therapy (IGRT); 8960 non-agammaglobulinemia patients on IGRT;

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 Takeda Manufacturing Austria AG and The Authors. *Journal of Medical Virology* published by Wiley Periodicals LLC.

14 428 patients without IGRT), and the neutralizing capacity of 1100 immunoglobulin lots against SARS-CoV-2 (“Wuhan” and *Omicron* strains), throughout 3 years. From the first (2020/2021) to the second (2021/2022) cold season, i.e., during the virus drift to the more contagious *Omicron* variants, an increase in case numbers was recorded that was comparable (~2- to 3-fold) for all three study groups. During the same period, immunoglobulin lots showed a profound nAb increase against the archetypal SARS-CoV-2 strain, yet only low levels of *Omicron* nAbs. Notably, shortly before the third (2022/2023) cold season, *Omicron*-neutralizing capacity of released immunoglobulin lots had plateaued at high levels. From the second to the third cold season, COVID-19 cases dropped markedly. While a ~6-fold case reduction was recorded for the groups of non-agammaglobulinemia patients on IGRT and IEI patients not receiving IGRT, the decline was ~30-fold for the group of agammaglobulinemia patients on IGRT. These findings suggest a substantial COVID-19-protective effect of IGRT, at least for distinct groups of antibody-deficient patients.

KEYWORDS

agammaglobulinemia, COVID-19, intravenous immunoglobulin, neutralizing antibodies, primary immunodeficiency, SARS-CoV-2

1 | INTRODUCTION

Neutralizing antibodies (nAbs) are a central component of the immune response against *severe acute respiratory syndrome coronavirus 2* (SARS-CoV-2) infection and, therefore, serve as an informative correlate of protection.¹ Conversely, individuals with a reduced or absent antibody response—such as those with agammaglobulinemia—are at significantly higher risk of dying due to coronavirus disease 2019 (COVID-19).^{2,3} For this and other conditions belonging to the group of primary or secondary immune disorders (PID, SID), the insufficient levels of circulating functional antibodies can be replenished via treatment with subcutaneous or intravenous immunoglobulins (SCIG, IVIG), highly concentrated immunoglobulin G (IgG) preparations which are produced by plasma fractionation. The antibody spectrum of SCIG and IVIG is a reflection of pathogens and vaccines to which the plasma donor collective had previously been exposed. As thousands of individual donations are pooled to yield a single SCIG or IVIG lot, immunocompromised patients receive a drug that should conceptually protect them against a wide variety of circulating bacterial and viral infections.

This powerful safeguarding approach is, however, challenged when a new pathogen emerges or is subject to mutation. Indeed, it was shown that IVIG preparations released during the first months of the COVID-19 pandemic were lacking any SARS-CoV-2 neutralization.⁴ This was followed by a pronounced potency increase in the second year of the pandemic, first due to the increased fraction of SARS-CoV-2 convalescent plasma (CP) donors,⁵ then additionally because of the broadly rolled out COVID-19 vaccination campaigns,⁶ with a delay corresponding to the average time interval of 6 months between plasma donation

and release of the corresponding IVIG lot.⁵ Yet while SARS-CoV-2 nAbs in IVIG lots released in the cold season (October to March) of 2021/2022 had already reached substantial levels (i.e., normalized neutralization titers above 1:1000),⁷ the question as to which extent protection would be conferred to patients came into focus again due to the emergence of the *Omicron* variant of SARS-CoV-2. First detected in November 2021⁸ as virus variant most distant (at that time) to the archetypal “Wuhan” strain, several *Omicron* lineages and sublineages have evolved and have dominated infection events since then, owing to their increased contagiousness⁹ and high number of accumulated immune escape mutations.¹⁰ The latter fact is also mirrored in the drastically lowered *Omicron*-neutralizing capacity of plasma from SARS-CoV-2 convalescent individuals, and those twice vaccinated with first-generation COVID-19 vaccines.¹¹ Correspondingly, a ~20-fold lower potency to neutralize *Omicron* versus the original SARS-CoV-2 strain was also detected in IVIG lots released in spring 2022.⁷

While high vaccination coverage, adaptation of several vaccines towards *Omicron* and the high degree of SARS-CoV-2 convalescence have eased everyday life for the general population, the current “post-pandemic” situation is still worrisome for those with immunocompromised medical conditions: with most physical infection prevention measures having been repealed at a global scale, these patients more than ever are in need of effective prophylactic measures. Although the protective level of *Omicron* nAbs is yet to be determined, immunoglobulin replacement therapy (IGRT) could be a vital component of successful prophylaxis for those affected by PID/SID. To shed light on this issue, the present study evaluated a potential negative correlation between COVID-19 incidence decline and neutralizing antibody increase.

2 | MATERIALS AND METHODS

2.1 | IVIG preparations

Analyzed IVIG lots were 10% wt/vol preparations (i.e., 100 mg IgG/mL), either fractionated from plasma collected at Takeda (BioLife) plasma donation centers (source plasma) or obtained from whole-blood donations (recovered plasma). A total of 1001 IVIG lots produced from US plasma donations (Gammagard Liquid; Baxter Healthcare Corp.), and 99 IVIG lots manufactured from plasma of donors residing in central Europe (Austria, Germany, Czech Republic; KIOVIG; Baxter AG), released between March 2020 and February 2023, were tested for SARS-CoV-2 nAbs. Lots released from January 2022 onwards were additionally tested for nAbs against the *Omicron* variant.

2.2 | Measurement of SARS-CoV-2 Wuhan and *Omicron* nAbs

For neutralization assays, wild type (Wuhan) SARS-CoV-2 strain BavPat1/2020¹² and *Omicron* strain hCoV-19/Netherlands/NH-RIVM-71076/2021 (lineage B.1.1.529; European Virus Archive global [EVAg], REF 014V-04430) were employed. In-house stocks were generated by infection of Vero cells (Cat. No. 84113001, European Collection of Authenticated Cell Cultures, Porton Down, Salisbury, UK) and harvest of the supernatant upon appearance of robust virus-induced cytopathic effects (CPE). In this way, three virus seeds were generated sequentially; seed 3 was used to generate working seeds which were employed for neutralization assays. For neutralization assays, IVIG samples were 2-fold serially diluted in cell culture medium. These dilutions were mixed with an equal volume of virus working seed at 10^{3.0} tissue culture infectious doses 50% per milliliter (TCID₅₀/mL) and incubated for 150 min at room temperature. Subsequently, the mixtures were added onto Vero cells that had been seeded in 96-well microtiter plates (20 000 cells/well) on the same day. Each sample was analyzed in 10 dilutions with 8 replicate wells per dilution. After incubation for 5–7 days (36°C; humidified atmosphere with 5% CO₂), microscopic readout of CPE was conducted and the neutralization titer (μNT_{50}), i.e., the reciprocal sample dilution resulting in 50% virus neutralization, was determined using the Spearman-Kärber formula. To enable reliable comparison across distinct assays, normalized neutralization titers (norm. μNT_{50}) were generated via the use of an internal standard (STD; a plasma donation with SARS-CoV-2 nAbs) that was run in parallel with samples in each assay. Initially, for the STD, a “reference μNT_{50} ” was calculated from repeat neutralization assays; to normalize the μNT_{50} of samples from a particular assay, the sample μNT_{50} values were corrected (multiplied) with the ratio of the STD “reference μNT_{50} ” and the μNT_{50} of the STD from that assay. Design of the neutralization assays included several validity criteria, i.e., cell viability, confirmatory titration of input virus infectivity, and neutralization testing of an assay control.

2.3 | Retrieval of European Society for Immunodeficiencies (ESID)-registered COVID-19 cases

On November 13th, 2023, the ESID patient registry was queried for COVID-19 cases recorded between January 1st, 2020; and October 23rd, 2023. Retrieved cases were assorted to the following groups: (i) agammaglobulinemia patients on IGRT, (ii) non-agammaglobulinemia patients on IGRT, (iii) patients not receiving IGRT. COVID-19 was ascertained via a positive SARS-CoV-2 RT-qPCR test for agammaglobulinemia patients or—for the other two groups—via PCR or a serological test. All patients or their legal representatives had given their informed consent (based on IRB approval No. 493/14 of the Ethical Committee Freiburg) to participate in the ESID registry study. Clinical and laboratory data were retrieved from retrospective chart review at the ESID documenting centers and entered online into the registry.¹³

2.4 | Retrieval of COVID-19 cases in general populations

Weekly confirmed COVID-19 cases were exported from the COVID-19 Data Explorer provided on www.ourworldindata.org and summed up for the locations “Europe” and “United States” for the time intervals between October 1st to March 31st, for Fall/Winter seasons of 2021/2022 and 2022/2023, respectively.

2.5 | Data preparation, visualization, and statistical analysis

ESID registry data was extracted and arranged with DbVisualizer Pro (Version 12.0.6). Neutralization assay and ESID registry data were combined using Microsoft Excel (Version 2310); visualization including descriptive statistics was done using GraphPad Prism (Version 8.4.3). Statistical testing was conducted using Minitab.

3 | RESULTS

3.1 | Seasonality of COVID-19 in immunocompromised patient cohorts

A total number of 981 agammaglobulinemia (mostly X-linked agammaglobulinemia) patients receiving IGRT was retrieved from the ESID-registry; the group had a median age of 22 years (range: 0–92 years) and consisted—as expected—mainly of male individuals. The group of non-agammaglobulinemia patients receiving IGRT consisted of 8960 individuals with a median age of 33 years (range: 0–95 years) and a more balanced gender ratio; the most strongly represented disease categories were “Predominantly antibody disorders” (72%) and “Combined immunodeficiencies” (12%). The

group of patients not receiving IGRT consisted of 14 428 individuals with a median age of 20 years (range: 0–93 years), again had a rather balanced gender ratio and a broader dispersion of individuals among disease categories (Table 1). For patients registered within the ESID database, time of COVID-19 infection is documented via the date of the SARS-CoV-2 RT-qPCR or serological test. Considering the first 2 years of the pandemic, the development of COVID-19 cases per

month confirmed the increased disease burden during the colder half of the year, i.e., from October to March (Table 2). For instance, for the patient group without IGRT, 15 COVID-19 cases were recorded in spring and summer of 2020, increasing to 120 cases in the following cold season, dropping again to 37 cases in the subsequent 6 months, and then culminating to 212 cases recorded within October 2021 and March 2022. Similar oscillations were observed for the groups of agammaglobulinemia and non-agammaglobulinemia patients, both under IGRT (Table 2; Figure 1A). Although in the subsequent spring and summer period of 2022, again a drop in cases versus the preceding 6 months occurred, it was less pronounced than before and followed by further decreases up until the end of the period under study.

Over the entire observation time, 513 COVID-19 cases with information on the date of a positive PCR or seroconversion were recorded for patients not receiving IGRT, which accounts for ~4% of the total number of ESID registry entries assorted to that group (14 428; Table 2). This fraction was higher for agammaglobulinemia patients under IGRT (11%; 111 recorded COVID-19 cases, 981 ESID registry entries), with most cases (58, ~50%) recorded during the first *Omicron* season, i.e., at a time where nAb levels were only minor in the general population¹¹ and in released IVIG lots (Figure 1B). The overall percentage of COVID-19 cases for non-agammaglobulinemia patients under IGRT, for whom IVIG treatment might have more complex effects as antibody deficiencies are less pronounced, was in between the values of the two other studied groups (~9%; 813 recorded COVID-19 cases, 8960 ESID registry entries; Table 2).

TABLE 1 Demographic characteristics of patients with primary immune disorders (PID).

Agammaglobulinemia patients on IGRT (AGAMMA + IGRT)	
N (female; male)	981 (65; 916)
median age (range) [year]	22 (0–92)
Non-agammaglobulinemia patients on IGRT (NON-AGAMMA + IGRT)	
N (female; male; unknown)	8960 (4536; 4421; 3)
median age (range) [year]	33 (0–95)
Main disease category	N (%)
Combined immunodeficiencies	1085 (12.1)
Predominantly antibody disorders	6325 (71.6)
Diseases of immune dysregulation	305 (3.4)
Phagocytic disorders	103 (1.2)
Defects in innate immunity	130 (1.5)
Autoinflammatory disorders	50 (0.6)
Complement deficiencies	26 (0.3)
Other well defined PIDs	855 (9.5)
Unclassified Immunodeficiencies	81 (0.9)
Patients without IGRT (NO IGRT)	
N (female; male; unknown)	14 428 (6387; 8040; 1)
median age (range) [year]	20 (0–93)
Main disease category	N (%)
Combined immunodeficiencies	1221 (8.5)
Predominantly antibody disorders	5120 (35.5)
Diseases of immune dysregulation	1308 (9.1)
Phagocytic disorders	1930 (13.4)
Defects in innate immunity	397 (2.8)
Autoinflammatory disorders	855 (5.9)
Complement deficiencies	833 (5.8)
Bone marrow failure	2 (0.0)
Other well defined PIDs	2523 (17.5)
Unclassified Immunodeficiencies	239 (1.7)

Note: Data was retrieved from the ESID registry and assorted to three groups (light blue) based on types of inborn error of immunity and immune replacement therapy (IGRT). Main disease categories were defined based on the International Union of Immunological Societies (IUIS) classification. Abbreviation: ESID, European Society for Immunodeficiencies.

3.2 | COVID-19 cases in immunocompromised patients and SARS-CoV-2 wild type /Omicron nAbs in IVIG

When comparing the first pandemic cold season (October 2020 to March 2021) to the second (October 2021 to March 2022), all three immunocompromised patient cohorts exhibited a rather similar ~2- to 3-fold increase in COVID-19 cases (Table 1). In contrast, from the second to the third cold season (October 2022 to March 2023), a marked reduction in COVID-19 cases occurred, yet to different extent: While a ~6-fold reduction was noted for the group of patients not receiving IGRT (from 212 to 38 cases), the decrease of COVID-19 incidents in the group of agammaglobulinemia patients under IGRT was ~30-fold (from 59 to 2 cases) (Figure 1A and Table 1). The hypothesis of a more prominent reduction in COVID-19 infections in the agammaglobulinemia patients under IGRT group was tested by comparing the annual occurrences against the group of non-IGRT treated patients. The lack of similarity in the ratios of cases was statistically significant (χ^2 -test for association; $p = 0.022$; Table 3). For the group of non-agammaglobulinemia patients under IGRT, the decrease was similar to the group of patients without IGRT (~6-fold: from 346 to 58 cases; Table 1). For the groups of patients not receiving IGRT and the group of non-agammaglobulinemia patients under IGRT, the decrease was also quite similar to the drop of

TABLE 2 COVID-19 cases over time in three groups of immunocompromised patients: Agammaglobulinemia with immunoglobulin replacement therapy ("AGAMMA + IGRT"), non-agammaglobulinemia with immunoglobulin replacement therapy ("NON-AGAMMA + IGRT"), no immunoglobulin replacement therapy ("NO IGRT").

YYYY-MM	AGAMMA + IGRT (N = 981) COVID-19 incident count (based on positive PCR or serological result)		NON-AGAMMA + IGRT (N = 8960)		NO IGRT (N = 14 428)		
2020-03	0		3		3		
2020-04	2	5	3	21	0	15	Spring/ summer season 2020
2020-05	0		1		4		
2020-06	2		5		2		
2020-07	0		0		2		
2020-08	1		4		2		
2020-09	0		8		5		
2020-10	4	22	25	166	9	120	Fall/winter season 2020/21
2020-11	4		35		32		
2020-12	5		28		23		
2021-01	3		33		36		
2021-02	1		23		10		
2021-03	5		22		10		
2021-04	0	3	22	37	12	37	Spring/ summer season 2021
2021-05	1		2		10		
2021-06	1		2		7		
2021-07	1		4		1		
2021-08	0		3		2		
2021-09	0		4		5		
2021-10	1	59	11	346	10	212	Fall/winter season 2021/22
2021-11	1		28		12		
2021-12	3		41		22		
2022-01	16		95		60		
2022-02	19		70		58		
2022-03	19		101		50		
2022-04	4	19	64	177	20	84	Spring/ summer season 2022
2022-05	5		26		9		
2022-06	5		26		19		
2022-07	2		31		21		
2022-08	4		15		8		
2022-09	0		15		7		
2022-10	1	2	20	58	10	38	Fall/winter season 2022/23
2022-11	0		9		9		
2022-12	1		10		6		
2023-01	0		5		6		
2023-02	0		5		5		
2023-03	0		9		2		

(Continues)

TABLE 2 (Continued)

YYYY-MM	AGAMMA + IGRT (N = 981) COVID-19 incident count (based on positive PCR or serological result)		NON-AGAMMA + IGRT (N = 8960)		NO IGRT (N = 14 428)		
2023-04	1	1	2	5	1	4	Spring/ summer season 2023
2023-05	0		3		3		
2023-06	0		0		0		
2023-07	0		0		0		
2023-08	0		0		0		
2023-09	0		0		0		
2023-10	0		0		0		
	111		813		513		Total

Note: Data was extracted from the ESID registry and sorted according to date of positive SARS-CoV-2 test. Sum of cases across six months (either Spring/summer or Fall/winter season) is highlighted by bold and italic numbers.

Abbreviations: ESID, European Society for Immunodeficiencies; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

infections in the general populations of Europe (~6-fold: from 118 167 912 to 21 001 100 cases) and the United States (~5-fold: from 36 718 131 to 7 914 262 cases). Regarding IVIG lots, while only baseline levels of SARS-CoV-2 nAbs were present in IVIG released during the first pandemic cold season (October 2020 to March 2021), pronounced anti-SARS-CoV-2 potency was evident in the second cold season (October 2021 to March 2022), e.g., the mean normalized neutralization titer of all lots released in March 2022 was ~4270 (Figure 1B). This was subject to some further, i.e., approximately 3-fold, increase until the third cold season (e.g., mean normalized neutralization titer of ~12 600 in February 2023). A much more pronounced, ~14-fold increase was, however, evident with respect to *Omicron*-neutralizing capacity, i.e., mean normalized neutralization titers went up from ~270 in March 2022 to ~3870 at the end of the third cold season (February 2023; Figure 1B). In summary, the markedly reduced number of COVID-19 infections amongst immunocompromised patients, particularly those diagnosed with agammaglobulinemia, recorded for the last (third) cold season, coincides with a phase where released IVIG lots present with SARS-CoV-2 and also *Omicron* nAbs at consistently high levels.

4 | DISCUSSION

From the beginning of the COVID-19 pandemic it has been evident that immunocompromised individuals constitute an especially vulnerable population group, despite the considerable heterogeneity of underlying etiologies. The exceptionally fast development and approval of several COVID-19 vaccines has substantially reduced the global burden of disease, not only in the general population, but also for patients with PID or SID. In this respect, it is important to remember that all of the available COVID-19 vaccines except live vaccines are explicitly recommended for individuals with inborn errors of immunity (IEI).¹⁴ However, longitudinal observations have revealed that, for patients with IEI, there is still a need for additional

measures. For instance, a large study on immunocompromised populations versus the general population found that, even though the percentage of immunocompromised individuals vaccinated with ≥ 3 doses was higher, the rate of severe COVID-19 outcomes was markedly increased, also after adjusting for confounding variables such as age, sex, and the number of non-immunocompromising comorbidities.¹⁵

Longer and more severe disease courses have also been specifically reported for the subgroup of patients suffering from a primary antibody deficiency (PAD; for review, see Paris¹⁶). In these subjects, the vaccination-induced antibody response is reduced to variable extent,¹⁷ with SARS-CoV-2 antibodies, particularly nAbs, being essentially absent for patients suffering from X-linked agammaglobulinemia.¹⁸ A systemic compensation of the missing antibodies is thus indicated especially for this patient subgroup.

During the first 2 years of the pandemic, monoclonal antibodies (mAbs) directed against the SARS-CoV-2 spike (S) protein were developed and authorized for post-exposure prophylaxis of immunocompromised individuals,¹⁹ as well as treatment.²⁰ However, the subsequent evolution of the virus, culminating in the global spread of *Omicron*, revealed the fragility of approaches relying on a single or two antigenic determinants, as none of the authorized mAbs was still able to neutralize *Omicron* subvariants that became prevalent in late 2022.²¹ Consequentially, all of these mAb preparations are no longer recommended for COVID-19 treatment or prophylaxis.²²

Even before mAbs were available, COVID-19 patients have been treated with CP, albeit with conflicting results in terms of clinical efficacy. The discrepancies in outcome have meanwhile been linked to the time of treatment onset,²³ and also to the potency level of the administered CP,²⁴ with early administration of plasma containing high SARS-CoV-2 nAb levels being most promising. Of note, vaccination induces higher titers than SARS-CoV-2 infection;²⁵ thus plasma used for transfusion ideally should be collected from vaccinated, convalescent donors. Given the high levels of both endemic infection and COVID-19 vaccination coverage, the majority




FIGURE 1 Temporal development of COVID-19 cases in subgroups of immunocompromised patients and SARS-CoV-2 neutralizing antibodies. (A) Course of COVID-19 cases among ESID-registered immunocompromised patients over time, shown for agammaglobulinemia subjects on immunoglobulin replacement therapy (“AGAMMA + IGRT”; red triangles) and subjects not receiving immunoglobulin replacement therapy (“NO IGRT”; gray circles). (B) SARS-CoV-2 neutralizing (blue) and Omicron neutralizing (red) potency of 10% IVIG lots released between March 2020 and February 2023. Subgroups of IVIG manufactured from plasma collected in the US or EU countries are depicted as circles and squares, respectively. Data is shown as geometric means of normalized neutralization titers \pm 95% confidence interval. COVID-19, coronavirus disease 2019; ESID, European Society for Immunodeficiencies; IGRT, immunoglobulin replacement therapy; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

of individuals donating plasma for fractionation falls into this group. In addition, however, IVIG and SCIG preparations come with a \geq 10-fold enriched antibody concentration compared to CP, which—together with their superior safety profile—makes them a preferable treatment option.

Besides COVID-19 treatment of especially vulnerable groups, the present study argues for a beneficial effect of IGRT in a

prophylactic setting for certain groups of patients with IEI, as explained below: One of the main differences between the Fall/Winter seasons 2020/21 and 2021/22 was the shift towards the more contagious *Omicron* variants of SARS-CoV-2.⁹ Although SARS-CoV-2 nAbs in IVIG released in the latter period had already reached substantial levels (Figure 1B), these had only limited effect due to the antigenic changes associated with the then-circulating *Omicron*

TABLE 3 Chi-square test for differences in frequency distribution between agammaglobulinemia patients on immunoglobulin replacement therapy (IGRT) and patients not receiving IGRT.

Cold season		Patient group		Total
		AGAMMA + IGRT	NO IGRT	
2020/21	Count	22	120	142
	<i>Expected count</i>	<i>26.02</i>	<i>115.98</i>	
	<i>Contribution to Chi-square</i>	<i>0.6204</i>	<i>0.1392</i>	
2021/22	Count	59	212	271
	<i>Expected count</i>	<i>49.65</i>	<i>221.35</i>	
	<i>Contribution to Chi-square</i>	<i>1.7594</i>	<i>0.3947</i>	
2022/23	Count	2	38	40
	<i>Expected count</i>	<i>7.33</i>	<i>32.67</i>	
	<i>Contribution to Chi-square</i>	<i>3.8747</i>	<i>0.8692</i>	
Total		83	370	453
	Chi-square test	Chi-square	DF	p
	Pearson	7.658	2	0.022

Note: Data was extracted from the ESID registry and assorted to pandemic cold seasons (October to March) of 2020/21, 2021/22, and 2022/23; according to date of positive SARS-CoV-2 test. Actual case counts and statistical test results are highlighted in bold, while expected counts per subgroup and contribution to Chi-square are shown in italic.

sublineages. Correspondingly, between these two cold seasons, cases recorded in the ESID registry increased similarly, i.e., ~2- to 3-fold, for patients with IEI with and without IGRT (Table 1). In the subsequent Fall/Winter season 2022/23, immune responses to *Omicron* variants had been widely established in the general population, a considerable fraction of which was then also boosted with adapted COVID-19 vaccines. As a consequence, the risk of infection was reduced, which is reflected by the markedly decreased number of ESID-registered COVID-19 cases, when compared to the preceding Fall/Winter season 2021/22, across all of our study groups (Table 1), as well as in the general European and US population. The decrease was approximately 6-fold for the groups of patients with IEI without IGRT and the group of non-agammaglobulinemia patients receiving IGRT, comprising patients who, on average, can be assumed to mount at least a partial antibody response subsequent to infection/vaccination (in contrast to the essentially absent antibody response of patients in the "AGAMMA + IGRT" group). While the ~6-fold decrease of both groups was comparable to the decline in the general population, we recorded a much more pronounced (~30-fold) decline in COVID-19 cases amongst agammaglobulinemia patients with IGRT. The diverging behavior of annual occurrences between the group of AGAMMA + IGRT patients and those not receiving IGRT was significant ($p = 0.022$); and the individual χ^2 -contributions

indicate that the lower count of infections in the AGAMMA + IGRT group in Fall/Winter 2022/23 is the main driver for the significance (individual χ^2 contribution = 3.9). It is proposed that this discrepancy is at least partly due to IVIG-mediated antibody replenishment in individuals who are largely incapable of mounting an antibody response to pathogens by themselves, as—in contrast to the preceding Fall/Winter season 2021/22—the final cold season examined in our study was the first with a sufficient match between acutely circulating SARS-CoV-2 variants (i.e., *Omicron*) and the nAb spectrum of IVIG lots released at the same time (Figure 1B).

The fact that only IVIG preparations manufactured by a single company have been analyzed is a limitation of the present work, as the investigated patient groups also received IVIG from other manufacturers. However, in a recent study that evaluated IVIG and SCIG lots from several companies, only minor variation of SARS-CoV-2 binding antibody levels was shown for different products, while a clear correlation between antibody levels and expiration date (and thus manufacturing date) was found.²⁶ This is in line with our present and earlier studies^{4–7} on SARS-CoV-2 nAbs. It must further be emphasized that the time between lot release and administration is traditionally short for IVIG, owing to its notoriously insufficient availability, a situation that was even more aggravated during the COVID-19 pandemic.²⁷ Thus, it can be assumed that IVIG lots with robust *Omicron* nAb levels released during the third pandemic fall/winter season have been administered to patients fast. Since the occurrence of the first *Omicron* variants—such as the B.1.1.529 strain employed in the present study—the virus has seen further development, with BQ.1 and XBB.1.5 variants dominating infections in the third pandemic fall/winter season.²⁸ However, it has to be noted that the main antigenic changes occurred with the advent of *Omicron*. Further, it is fair to reason that also beyond the end of our study period (February 2023), nAbs against currently circulating *Omicron* sublineages remain high in immunoglobulins, given the recent infections of plasma donors with these "younger" virus types, as well as the rollout of *Omicron*-adapted vaccine variants, both leading to a constant "auto adjustment" of the SARS-CoV-2 nAb spectrum in IVIG and SCIG.²⁹

In addition to the antibody-mediated defense mechanisms against SARS-CoV-2, contributions by the cellular adaptive immune system have meanwhile been elucidated. For instance, such T-cell mediated responses were shown to confer cross-variant protection in mice independent of B-cell responses.³⁰ On the other hand, the importance of antibody-mediated antiviral effects has been demonstrated, e.g., via the high efficacy of treatment of symptomatic infections with S protein-targeting mAbs at a time when the virus had not yet drifted towards *Omicron*.³¹ Intuitively, this mechanism is especially important for agammaglobulinemia patients who are not able to mount an own antibody response.

Finally, the retrospective approach of data retrieval from the ESID registry is a limitation of the present endeavor; for instance, a stratification of patients according to number of received COVID-19 vaccinations or treatment with mAbs is not possible as these parameters are not captured within the ESID database. However,

the results presented should be considered to set the base for future prospective investigations, which, for example, could be directed towards pinpointing a protective *Omicron* nAb threshold.

Provided that *Omicron* sublineages will remain dominant, i.e., that the virus is not subject to significant further evolution, the present work supports the notion that IVIG lots released since the end of 2022 are constantly endowed with high neutralizing capacity against circulating SARS-CoV-2 strains. These levels likely are effective in the prophylactic setting, e.g., when periodically administered as in IEI/PAD, particularly in cases where IVIG and SCIG constitute a treatment well-matched to the pathology, such as for individuals suffering from agammaglobulinemia. Future investigations and maybe clinical trials might further corroborate these findings.

AUTHOR CONTRIBUTIONS

Isabelle Meyts, Mikko R. J. Seppänen, Fabio Candotti, Marta Kamieniak, Thomas R. Kreil, and Markus G. Seidel conceptualized the study. Gerhard Kindle extracted and analyzed data from the ESID registry. Michael Karbiener oversaw laboratory experiments and conducted data analyses. Reinhard Ilk conducted statistical analysis. Michael Karbiener and Thomas R. Kreil drafted the manuscript, with input from Gerhard Kindle, Markus G. Seidel, Isabelle Meyts, Mikko R. J. Seppänen, Reinhard Ilk, Marta Kamieniak, and Fabio Candotti. The ESID-COVID Consortium contributed patient data. All authors approved the final manuscript version for publication.

ACKNOWLEDGMENTS

The contributions of the entire Global Pathogen Safety team, most notably Simone Knotzer, Jasmin de Silva, Stefan Pantic, Elisabeth List, Nicole Rameder, Cornelia Lackner (neutralization assays), Veronika Sulzer, Sabrina Brandtner (cell culture), Eva Ha and Alexandra Schlapschy-Danzinger (virus culture), Kathrin Nagl (IG logistics) are gratefully acknowledged. Wild type (Wuhan) SARS-CoV-2 strain BavPat1/2020 and *Omicron* SARS-CoV-2 strain hCoV-19/Netherlands/NH-RIVM-71076/2021, lineage B.1.1.529 were sourced via the European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement no. 871029 and were kindly provided by Christian Drosten and Victor Corman (Charité Universitätsmedizin, Institute of Virology, Berlin, Germany) and Chantal Reusken (National Institute for Public Health and the Environment, RIVM, Bilthoven, Netherlands), respectively.

ESID-COVID Consortium Collaborators

Abd Elaziz Dalia, Abdelkader Sohilla Lofty M, Abitbol Avigaelle, Hassan Abolhassani, Abraham Lalash, Abuzakouk Mohamed, Achir Moussouni Nabila, Afonso Veronica, Agyeman Philipp, Ahlmann Martina, Aiuti Alessandro, Akl Abila, Aksu Güzide, Albers Kim, Albert Michael, Alecsandru Meda Diana, Aleinikova Olga, Aleshkevich Svetlana, Allende Luis, Alligon Mickael, Allwood Zoe, Alsina Manrique de Lara Laia, Ambrosch-Barsoumian Daniela, Ameshofer Lisa, Amour Kenza, Anadol Evrim, Ananthachagaran Ariharan, Andriamanga Chantal, Andris Julia, Andritschke Karin, Angelini Federica,

Ankermann Tobias, Apel Katrin, Arami Siamak, Ardeniz Ömür, Arkwright Peter, Arnold Karina, Ascherl Rudolf, Assam Najla, Assia-Batzir Nurit, Atschekzei Faranaz, Aumann Sybille, Aumann Volker, Aurivillius Magnus, Ausserer Bernd, Avcin Tadej, Aydemir Sezin, Aygören-Pürsün Emel, Ayvaz Deniz Cagdas, Azevedo Amaral Carolina Brito de, Azzari Chiara, Babacar Lo, Bach Perrine, Bachmann Sophie, Bader Peter, Bakhtiar Shahrzad, Bancé Renate, Bangs Catherine, Baratault Merlin Simsen, Barfusz Katerina, Baris Safa, Barlan Isil B., Bartsch Michaela, Baumann Helge, Baumann Ulrich, Baumeister Veronika, Baxendale Helen, Bazen Suzanne, Beaurain Beatrice, Beauté Julien, Beck Norbert, Becker Brigitta, Becker Christian, Behrends Uta, Beider Renata, Beier Rita, Belke Luisa, Bellert Sven, Belohradsky Bernd H., Ben Slama Lilia, Ben-Bouazid Aouatef, Berdous-Samed Thamila, Bergils Jan, Berglöf Anna, Bergman Peter, Bernatoniene Jolanta, Bernatowska Ewa, Bernat-Sitarz Katarzyna, Bernbeck Benedikt, Bethune Claire, Beuckmann Kai, Bhole Malini, Biegner Anika-Kerstin, Bielack Stefan, Bienemann Kirsten, Bigl Arndt, Bigorgne Amélie, Bijl Marc, Binder Nadine, Bitzenhofer-Grüber Michaela, Blanchard Rohner Geraldine, Blank Dagmar, Blattmann Claudia, Blau Julia, Blaziene Audra, Blazina Stefan, Blume Roswitha, Boardman Barbara, Bode Sebastian, Boelens Jaap-Jan, Boesecke Christoph, Bogaert Delfien, Bogner Johannes, Bohynikova Nadezda, Booth Claire, Bordon Victoria, Borkhardt Arndt, Borte Michael, Borte Stephan, Bossaller Lukas, Bossard Madeleine, Botros Jeannet, Boucherit Soraya, Boutros Jeannette, Boyarchuk Oksana, Boyman Onur, Boztug Kaan, Braschler Thomas, Bravo Sophie, Bredius Robbert, Bright Philip, Brodzski Nicholas, Brodt Grit, Brolund Allan, Brosselin Pauline, Brummel Bastian, Brunner Jürgen, Bruns Roswitha, Brun-Schmid Sonja, Buchta Christina, Buck Dietke, Bücken Aileen, Buckland Matthew, Bührlen Martina, Burdach Stefan, Burns Siobhan, Burton Janet, Caminal Luis, Cancrini Caterina, Canessa Clementina, Cant Andrew J., Cantoni Nathan, Capilna Brindusa, Caracseghi Fabiola, Caragol Isabel, Carbone Javier, Carrabba Maria, Chamberlain Latanya, Chantrain Christophe, Chapel Helen, Chassot Julie, Chee Ronnie, Chinello Matteo, Chopra Charu, Chovancova Zita, Christmann Martin, Chrzanowska Krystyna, Ciznar Peter, Claes Karlien, Classen Carl Friedrich, Classen Martin, Cochino Alexis-Virgil, Corbacioglu Selim, Cordeiro Ana Isabel, Cordier Wynar Donatienne, Core Claire, Costes Laurence, Coulter Tanya, Courteille Virginie, Cristina Maria, Cucuruz Maria, Dabrowska Leonik Nel, Dähling Mandy, Daly Mary Louise, Daniel Claudia-Sabrina, Danieli Maria, Danieli Maria Giovanna, Darroch James, Davies Graham, de Baets Frans, De Boeck Christiane, De Gracia Javier, De Gracia Roldan Javier, de Nadai Narimene, de Schutter Iris, De Vergnes Nathalie, de Vries Esther, Debert Theo, Debré Marianne, Defila Corina, Deimel Judith, Delaplace Diane, Dellepiane Rosa Maria, Dellert Nelli, Delliera Laura, Delor Anita, Demel Ulrike, Dempster John, den Os M. M., Dengg Rosmarie, Desisa Sora Asfaw, Desta Alexandra, Detkova Drahomira, Dewerchin Maite, Dieli Crimi Romina, Dilloo Dagmar, Dimitriou Florentia, Dinser Jasmin, Dipani Nabila, Dirks Johannes, Dittrich Anna-Maria, Djermane Lylia, Dogru Yagmur, Dogu Esin Figen, Dombrowski Angelika, Döring Michaela, Drabe Camilla Heldbjerg, Drerup Susann, Drexel Barbara, Driessen G. J. A., Dücker Gregor,

Dudoit Yasmine, Duppenhaler Andrea, Durandy Anne, Ebetsberger-Dachs Georg, Ecser Mate Barnabas, Edgar J. David, Eekman Maartje, Ehl Stephan, Ehrat Rosanna, Eisl Eva, Ekwall Olov, El Hawary Rabab, Elbe Sarina, Elcombe Suzanne, Eldash Alia, Eldeen Youssif Alkady Radwa Salah, El-Helou Sabine M, Ellerbroek P. M., Elling Roland, Elliott Jane, El-Marsafy Aisha, Engelhardt Angelika, Ernst Diana, Ersoy Fügen, Esper Stefanie, Esteves Isabel, Exley Andrew, Faber Martin, Fabio Giovanna, Fahrni Gaby, Faletti Laura Eva, Farber Claire-Michele, Faria Emilia, Farkas Henriette, Farmaki Evangelia, Faßhauer Maria, Fasth Anders, Fätkenheuer Gerd, Faustmann Stefanie, Fecker Gisela, Feighery Conleth, Feiterna-Sperling Cornelia, Fernandez-Cruz Perez Eduardo, Ferreira Concalo Cordeiro, Ferster Alice, Feuchtinger Tobias, Feyen Oliver, Finke Daniela, Fischer Alain, Fitter Sigrid, Flaschberger Stefan, Fleckenstein Lucia, Föll Dirk, Fontana Adriano, Forino Concetta, Förster-Waldl Elisabeth, Franchet Nora, Freitag Dagmar, Frey Urs P., Friedel Elisabeth, Friedrich Wilhelm, Frisch Barbara, Frischknecht Lukas, Fritzemeyer Stephanie, Gagro Alenka, Gahr Manfred, Gambineri Eleonora, Gamper Agnes, Gams Franziska, Ganzow Astrid, Garcez Tomaz, Garcia Prat Marina, Gardulf Ann, Garibay Janine, Garwer Birgit, Gasteiger Lukas, Gathmann Benjamin, Gathmann Jonathan, Gebauer Corinna, Geberzahn Linda, Geikowski Tilman, Geisen Ulf, Gemander Christiane, Gennery Andrew R., Gerisch Marie, Gernert Michael, Gerrer Katrin, Gerschmann Stev, Ghosh Sujal, Giannini Carolin, Gil Herrera Juana, Girndt Matthias, Girschbach Ramona, Girschick Hermann, Gkantaras Antonios, Gkoukourelas Ioannis, Gładysz Dominika, Gnodtke Elisabeth, Goda Vera, Goddard Sarah, Goebel Daniela, Goffard Jean-Christophe, Goldacker Sigune, Gollowitsch Eva Maria, Gomes Manuella, Gompels Mark, Gonzalez Granado Luis Ignacio, González Míriam, Gordins Pavels, Göschl Lisa, Gossens Lucy, Gößling Katharina, Gowin Ewelina, Graafen Lea, Graca Leo, Graf Dagmar, Graf Norbert, Grange Elliot, Grashoff H.Anne, Greil Johann, Grigoriadou Sofia, Grimbacher Bodo, Gronlund Helen, Groß-Wieltsch Ute, Guerra Teresa, Guevara-Hoyer Kissy, Guibert Noemie, Gülnur Birgit, Güngör Tayfun, Guseva Marina, Guzman David, H. Haverkamp Margje, Haag Marcel, Haase Gabriele, Haenicke Henriette, Haerynck Filomeen, Hafsa Ines, Hagin David, Hallek Michael, Hammarström Lennart, Hancioglu Gonca, Handgretinger Rupert, Hanitsch Leif G., Hansen Susanne, Hariyan Tetyana, Harrer Thomas, Hassunah Pia, Hatzistilianou Maria, Hauck Fabian, Hauser Thomas, Hayman Grant, Heath Paul, Hedrich Christian, Heeg Maximilian, Heike Michael, Heimbrodrt Martin, Heine Sabine, Heining Ulrich, Heinrich Christian, Heinz Valerie, Heitger Andreas, Helbert Matthew, Helbling Arthur, Hellige Antje, Hempel Julia, Henderson Karen, Henes Jörg, Henneke Philipp, Hennig Christian, Henrichs Karin, Herbst Martin, Hermann Walter, Hermine Olivier, Hernández Anja, Hernandez Manuel, Heropolitanska Edyta, Herriot Richard, Herrmann Friedrich, Herwadkar Archana, Hess Christoph, Hess Ursula, Hesse Sebastian, Higgins Sonja, Hilfanova Anna, Hilpert Sophie, Hintze Chantal, Hlaváčková Eva, Hodl Isabel, Hodzic Adna, Hoernes Miriam, Hoffmann Christina, Holbro Andreas, Höllinger Christiane, Holtsch Lisa, Holzer Ursula, Holzinger Dirk, Hönig Manfred, Hönscheid Andrea, Horn Julia, Horneff Gerd, Hoyoux Claire, Hristova Nataliya, Hübel Kai, Hübner Angela, Huemer

Christian, Huissoon Aarnoud, Hülsmann Brigitte, Hundsdörfer Patrick, Huppertz Hans-Iko, Huß Kristina, Hussain Sadia, Husson Julien, Hüttner-Foehlich Tanja, Ijspeert Hanna, Ikinciogullari Aydan, İlknur Kökçü, Irga Ninela, Jablonka Alexandra, Jahnz-Rozyk Karina, Jakob Marcus, Jakoby Donate, Jandus Peter, Jansson Annette, Jaquet Melanie, Jardefors Helene, Jargulinska Edyta, Jauk Barbara, Jesenak Milos, Jilka Katharina, Jolles Stephen, Jones Alison, Jones Regina, Jonkman-Berk Birgit, Jönsson Göran, Joyce Hilary J., Juliana Pricillia, Kabesch Michael, Kager Leo, Kahlert Christian, Kaiser-Labusch Petra, Kakkas Ioannis, Kamitz Dirk, Kanariou Maria, Kanz Lothar, Karakoc-Aydiner Elif, Karanovic Boris, Kartal-Kaess Mutlu, Käser Elisabeth, Katzenstein Terese L., Kayserova Hana, Kelleher Peter, Kerre Tessa, Kilic Sara Sebnem, Kirchner Martina, Kiwit Simone, Kiykim Ayca, Klasen Jessica, Klauedel-Dreszler Maja, Klein Ariane, Klein Christoph, Kleine Ilona, Kleinert Stefan, Klein-Franke Andreas, Klemann Christian, Klima Marion, Kobbe Robin, Kocacik Uygun Dilara Fatma, Koch Melanie, Kochler Yvonne, Kohistani Naschla, Kojic Marina, Kolios Antonio, Kölsch Uwe, Koltan Sylwia, Kondratenko Irina, Königs Christoph, Konoplyannikova Julia, Kopac Peter, Kopp Jana, Körholz Dieter, Körholz Julia, Korte Pauline, Kostyuchenko Larysa, Kötter Ina, Kracker Sven, Králícková Pavlína, Kramm Christof, Kramme Philipp, Kreuz Wolfhart, Kriván Gergely, Kropshofer Gabriele, Krüger Renate, Krystufkova Olga, Ktistaki Maria, Kühl Jörn-Sven, Kühn Alexander, Kuijpers Taco W., Kuis Wietse, Kullmann Silke, Kulozik Andreas, Kumararatne Dinakantha, Kümmler Ria, Kündgen Andrea, Kurenko – Deptuch Magdalena, Kuss Paula Cosima, Kütükcüler Necil, Lafoix-Mignot Cécile, Lamers Beate, Lanbeck Peter, Landais Paul, Landwehr-Kenzel Sybille, Langemeyer Vanessa, Langer Thorsten, Lankisch Petra, Lanz Nadia, Lara Manrique de, Lara-Villacanas Eusebia, Laubenthal Lisa, Laws Hans-Jürgen, Leahy Ronan, Lee Jae-Yun, Lehmann Andrea, Lehberg Kai, Lehner Patricia, Leibfrit Hans, Leistner Leoni, Lesch Petra, Leutner Simon, Liatsis Manolis, Libai Véglová Linda, Liebel Johanna, Liese Johannes G., Linauskiene Kotryna, Linde Richard, Linßner Martina, Lippert Conrad Ferdinand, Litzman Jiri, Llobet Pilar, Lodin Tariq, Lokaj Jindrich, Longhino David, Longhurst Hilary, Lopes da Silva Susana, Lorenzen Catharina, Lortholary Olivier, Lougaris Vassilios, Löw Doris, Lubatschowski Annelie, Lucas Mary, Lutz-Wiegers Verena, Maaß Sabine, Maccari Maria Elena, Macura-Biegun Anna, Maerz Vanessa, Maggina Paraskevi, Mahlaoui Nizar, Mahrenholz Hannah, Maier Sarah, Makhlouf Mounia, Malfroot Anne, Malinauskiene Laura, Mannhardt-Laakmann Wilma, Manson Ania, Mantkowski Felicia, Manzey Petra, Marasco Carolina, Marcus-Mandelblit Nufar, Marg Wolfgang, Markelj Gasper, Marodi Laszlo, Marques José Goncalo, Marques Laura, Marschall Karin, Martinez de la Ossa Saenz-Lopez Rafael, Martínez Natalia, Martinez-Saguer Inmaculada, Martire Baldassarre, Marzollo Antonio, Masekela Refiloe, Masjosthusmann Katja, Masmás Tania Nicole, Matamoros Nuria, Mattern Jutta, Mau-Asam Pearl, McDermott Elizabeth, McIntosh Nichole, Meglic Karmen Mesko, Meijer Ruben, Meinhardt Andrea, Meshaal Safa, Messaoud Yasmina, Meyer Björn, Meyer-Olson Dirk, Micol Romain, Micoloc Bozena, Mielke Gudrun, Mignot Loic Le, Milito Cinzia, Misbah Siraj, Mohr Michael, Mohrmann Karina, Moin Mostafa, Molinos Luis, Möller Jana, Möller-Nehring

Sarah, Morbach Henner, Moschese Viviana, Moser Olga, Moshous Despina, Motkowski Radoslaw, Motwani Jayashree, Mouftah Galal Nermeen, Möglich Carmen, Mukhina Anna, Müller Christiane, Müller Eva, Müller Gabriele, Müller Hedi, Müller Ingo, Müller Thomas, Müller Zoe, Müller-Ladner Ulf, Müller-Stöver Sarah, Münstermann Esther, Murtra Garrell Núria, Muschaweck Moritz, Mutert Miriam, Nademi Zohreh, Naik Paru, Nàke Andrea, Nalda Andrea Martin, Nasrullayeva Gulnara, Naumann-Bartsch Nora, Nemitz Verena, Neubauer Andreas, Neubert Jennifer, Neumann Carla, Neves João Fabela, Niehues Tim, Niemuth Mara, Nieters Alexandra, Nieuwhof Chris, Nolkemper Daniela, Noorani Sadia, Noorlander Budde Adya, Notheis Gundula, Nowatsh Sanam Amelie, Obenga Gaele, Ocak Suheyla, Oker Mehmet, Oksenhendler Eric, Olbrich Peter, Olipra Anna, Omran Heymut, Oommen Prasad, Orosova Jaroslava, Oskarsdottir Solveig, Özsahin Hülya, Pac Malgorzata, Pachlopnik Schmid Jana, Pandolfi Franco, Papadopoulou-Alataki Efimia, Papatriantafillou-Schmieder Anna, Parra-Martinez Alba, Paschenko Olga, Pašić Srdjan, Pasnik Jarek, Patel Smita, Pavlík Martin, Paz Artal Estela, Peeters Anouk, Pereira da Silva Sara Branco, Perez-Becker Ruy, Perlhagen Markus, Peter Hans-Hartmut, Pfreundschuh Michael, Philippet Pierre, Picard Capucine, Pietrucha Barbara, Pietzsch Leonora, Pignata Claudio, Piquer Gibert Monica, Pirolt Kerstin, Plebani Alessandro, Pleguezuelo Daniel E., Pollok Katrin, Pommerening Helena, Popihh Daniela, Poplonek Aleksandra, Popp Marina, Porta Fulvio, Portegys Jan, Posfay-Barbe Klara, Potjewijd Judith, Poulheim Sebastian, Prader Seraina, Prämassing-Scherzer Petra, Prelog Martina, Prevot Johan, Price Arthur, Price Timothy, Proesmans Marijke, Provot Johan, Quinti Isabella, Raab Anna, Rack Anita, Raffac Stefan, Ramos Oviedo Eduardo, Randrianomenjanahary Philippe, Ranohavimparany Anja, Raptaki Maria, Rashidzadeh Roonaka, Rathwallner Margit, Reda Shereen, Redouane Nahida, Regateiro Frederico S., Reichenbach Janine, Reimers Bianca, Reinhardt Cornelia, Reinhardt Dirk, Reinprecht Anne, Reisli Ismail, Reiß Tamara, Renner Eleonore, Rezaei Nima, Richter Alex, Richter Darko, Rieber Nikolaus Peter, Rieckehr Nadja, Riedel Marion, Riescher Heidi, Rischewski Johannes, Ristl Nicole, Ritterbusch Henrike, Ritz Tanja, Rivier Francois, Rockstroh Jürgen K., Roesler Joachim, Rofiah Himatur, Rogerson Elizabeth, Rolfes Elisabeth, Roller Beate, Romanyshyn Yaryna, Rondelli Roberto, Roosens Fien, Rösen-Wolff Angela, Rösler Valentina, Roth Johannes, Rothoef Tobias, Roubertie Agathe, Rübsam Gesa, Rusch Stephan, Rutgers Abraham, Ryan Paul, Sach Gudrun, Sadeghi Kambis, Sahrbacher Ulrike, Saidi Angelika, Sanal Tezcan Özden, Sanchez-Ramon Silvia, Santos Juan Luis, Sargur Ravishankar, Savchak Ihor, Savic Sinisa, Schaaf Bernhard, Schaefer Marzena, Schäfe Christina, Scharbatke Eva, Schatorje Ellen, Schauer Uwe, Scheibenbogen Carmen, Scheible Raphael, Scheinecker Clemens, Schiller Romana, Schilling Beatrice, Schilling Freimut, Schlieben Steffi, Schmalbach Thilo, Schmalzing Marc Thomas, Schmid Pirmin, Schmidt Nadine, Schmidt Reinhold Ernst, Schmitz Monika, Schneider Dominik, Schneider Dominik T., Schneppenheim Reinhard, Scholtes Cathy, Schölvinck E. H., Schönberger Stefan, Schreiber Stefan, Schrijvers Rik, Schroll Andrea, Schruhl Simone, Schrum Johanna, Schubert Ralf, Schuh Sebastian, Schulz Ansgar, Schulz Claudia, Schulze

Koops Hendrik, Schulze-Sturm Ulf, Schumacher Eva-Maria, Schürmann Elvira, Schürmann Gesine, Schuster Volker, Schütz Catharina, Schwaneck Eva, Schwarz Klaus, Schwarz Tobias, Schwarze-Zander Carolynne, Schweigerer Lothar, Schwinger Wolfgang, Sediva Anna, Seebach Jörg, Seger Reinhard, Segerer Florian, Selle Barbara, Seneviratne Suranjith, Seny Gueye Mor, Shabanaj Hatidje, Sharapova Svetlana, Shcherbina Anna, Shillitoe Ben, Siepelmeyer Anne, Siepermann Kathrin, Simon Anna, Simon Arne, Simon-Klingenstein Katja, Simonovic Marija, Sitkauskiene Brigita, Skapenko Alla, Skarke Maiken, Skomska-Pawliszak Malgorzata, Slatter Mary, Smet Julie, Smith C. I. Edvard, Sobh Ali, Sobik Bettina, Sogkas Georgios, Sohm Michael, Solanich-Moreno Xavier, Soler Palacín Pere, Sollinger Franz, Somech Raz, Sonnenschein Anja, Soresina Annarosa, Sornsakrin Marijke, Soura Stavrieta, Spaccarotella Sabrina, Spadaro Guisepppe, Sparber-Sauer Monika, Specker Christof, Speckmann Carsten, Speidel Lisa, Speletas Matthaios, Stachel Klaus-Daniel, Stanislas Aurélie, Stapornwongkul Cynthia, Staus Paulina, Steck Regina, Steele Cathal, Steffin Herbert, Steiner Urs, Steinmann Sandra, Stevens Wim, Stiefel Martina, Stieger Sarah, Stiehler Sophie, Stimm Hermann, Stojanov Silvia, Stoll Matthias, Stoppa-Lyonnet Dominique, Strapatsas Tobias, Strauß Gabriele, Streiter Monika, Strik-Albers Riet, Strotmann Gaby, Suárez Casado Héctor, Subiza Jose Luis, Sundin Mikael, Sub Birgit, Sutter Fabienne, Szaflarska Anna, Szemkus Monika, Tamary Hannah, Tantou Sofia, Tarzi Michael D., Taschner Helga, Taucher Sabrina, Tedgard Ulf, Teixeira Carla, ten Berge RJM, Tenbrock Klaus, Tester Sabine, Tezcan Ilhan, Thalgueter Sonja, Thalhammer Julian, Thoma Katharina, Thomas Moira, Thomczyk Fabian, Thon Vojtech, Thrasher Adrian, Tierney Patricia, Tietsch Nadine, Tomic Mara, Tommasini Alberto, Tönnies Beate, Tony Hans-Peter, Trachana Maria, Trapp Carmen, Tricas Lourdes, Trindade Neves Maria Conceicao, Trischler Jordis, Ubieto Hugo, Uelzen Anett, Uhlmann Annette, Ullrich Jan, Ullrich Kurt, Ünal Ekrem, Urbanski Gerhard, Urschel Simon, Uszynska Aleksandra, Vacca Angelo, Vaganov N. N., Vagedes Daniel, Valicevic Stefanie, Vallelian Florence, van Beem Rachel T., van Damme Charlotte, van de Ven Annick, van den Berg J. Merlijn, van der Flier Michiel, van Dissel J. T., van Hagen P. M., van Montfrans J. M., van Ogtrop Geoffrey, van Rens Jacqui, van Riel Christel A. M. P., van Royen-Kerkhof Annet, van Well G.Th.J, Vasiliki Antari, Velbri Sirje, Vencken Jo, Ventura Alessandro, Vermeulen François, Vermeylen Christiane, Viemann Dorothee, Viereck Anja, Villa Anna, Vincke Jeroen, Vinnemeier-Laubenthal Lisa, Vo Thi Kim Duy, Vollbach Kristina, Volokha Alla, von Bernuth Horst, von Bismarck Philipp, Voss Rebecca, Voß Sandra, Vural Yüksel, Wachuga Heike, Wagner Norbert, Wagström Per, Wahle Matthias, Wahn Volker, Wapp Nadine, Warnatz Klaus, Warneke Monika, Warris Adilia, Wasmuth Jan-Christian, Wasserfallen Jean-Blaise, Wawer Angela, Weber Manfred, Weemaes Corrie M. R., Weidinger Stephan, Weiß Michael, Weißbarth-Riedel Elisabeth, Werner Antje, Wessel Sara, Westkemper Marco, Wicher Monika, Wickmann Lutz, Wiegert Sabine, Wiehe Monique, Wiehler Katharina, Wiesböck Lydia, Wiesik-Szewczyk Ewa, Williams Anthony, Winkler Beate, Winkler Christel, Winkler Martina, Winkler Melanie, Wintergerst Uwe, Wisgrill Lukas, Witte Josine de, Witte Torsten, Wittkowski Helmut, Wolf Barbara, Wölke Sandra,

Wolschner Christina, Wolska-Kusnierz Beata, Wood Philip, Workman Sarita, Worth Austen, Wortmann Michaela, Wuillemin Walter Alfred, Wulffraat Nico M., Wustrau Katharina, Wyndham-Thomas Chloé, Yegin Olcay, Yildiran Alisan, Yilmaz Denise, Young Patrick, Yucel Esra, Zečević Milica, Erić Želimir, Zepp Fred, Zetzsche Klaus-, Zeuner Rainald, Zielen Stefan, Zimmermann Martina.

CONFLICT OF INTEREST STATEMENT

Michael Karbiener, Reinhard Ilk, and Thomas R. Kreil are employees of Takeda Manufacturing Austria AG, Vienna, Austria, and have Takeda stock interest. Isabelle Meyts has received research funding from CSL Behring (paid to institution) as well as consultancy honorary from Takeda and CSL Behring, paid to Institution. Isabelle Meyts serves on an advisory board for Boehringer-Ingelheim. Marta Kamieniak is an employee of Takeda Development Center Americas, Inc. and a Takeda shareholder. MGS has received research funding from Amgen and Takeda (paid to institution), consultancy honorary from Pharming, Amgen, and Novartis, and a conference travel grant from CSL Behring.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Michael Karbiener  <http://orcid.org/0000-0002-8064-2489>

Gerhard Kindle  <https://orcid.org/0000-0003-0894-5327>

Isabelle Meyts  <https://orcid.org/0000-0003-1214-0302>

Mikko R. J. Seppänen  <https://orcid.org/0000-0001-9733-3650>

Fabio Candotti  <http://orcid.org/0000-0001-6399-6042>

Marta Kamieniak  <http://orcid.org/0009-0001-9931-2228>

Thomas R. Kreil  <http://orcid.org/0000-0001-9970-0987>

Markus G. Seidel  <https://orcid.org/0000-0003-0981-8661>

REFERENCES

1. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nature Med.* 2021;27:1205-1211. doi:10.1038/s41591-021-01377-8
2. Delavari S, Abolhassani H, Abolnezhadian F, et al. Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency. *J Clin Immunol.* 2021;41:345-355. doi:10.1007/s10875-020-00928-x
3. Meyts I, Buccioli G, Quinti I, et al. Coronavirus disease 2019 in patients with inborn errors of immunity: an international study. *J Allergy Clin Immunol.* 2021;147:520-531. doi:10.1016/j.jaci.2020.09.010
4. Schwaiger J, Karbiener M, Aberham C, Farcet MR, Kreil TR. No SARS-CoV-2 neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic. *J Infect Dis.* 2020;222:1960-1964. doi:10.1093/infdis/jiaa593
5. Farcet MR, Karbiener M, Schwaiger J, Ilk R, Kreil TR. Rapidly increasing severe acute respiratory syndrome coronavirus 2 neutralization by intravenous immunoglobulins produced from plasma collected during the 2020 pandemic. *J Infect Dis.* 2022;226:1357-1361. doi:10.1093/infdis/jiab142
6. Karbiener M, Farcet MR, Schwaiger J, et al. Highly potent SARS-CoV-2 neutralization by intravenous immunoglobulins manufactured from Post-COVID-19 and COVID-19-Vaccinated plasma donations. *J Infect Dis.* 2021;224:1707-1711. doi:10.1093/infdis/jiab482
7. Farcet MR, Karbiener M, Knotzer S, Schwaiger J, Kreil TR. Omicron severe acute respiratory syndrome coronavirus 2 neutralization by immunoglobulin preparations manufactured from plasma collected in the United States and Europe. *J Infect Dis.* 2022;226:1396-1400. doi:10.1093/infdis/jiac358
8. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. *Nature.* 2022;603:679-686. doi:10.1038/s41586-022-04411-y
9. Gili R, Burioni R. SARS-CoV-2 before and after Omicron: two different viruses and two different diseases? *J Transl Med.* 2023;21:251. doi:10.1186/s12967-023-04095-6
10. Parsons RJ, Acharya P. Evolution of the SARS-CoV-2 Omicron spike. *Cell Rep.* 2023;42:113444. doi:10.1016/j.celrep.2023.113444
11. Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D. Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources. *Nat Commun.* 2022;13:6478. doi:10.1038/s41467-022-33864-y
12. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *Lancet Infect Dis.* 2020;20:920-928. doi:10.1016/s1473-3099(20)30314-5
13. Scheible R, Rusch S, Guzman D, Mahlaoui N, Ehl S, Kindle G. The NEW ESID online database network. *Bioinformatics (Oxford, England).* 2019;35:5367-5369. doi:10.1093/bioinformatics/btz525
14. European Society for Immunodeficiencies, ESID COVID-19 Statement, March 2022. <https://esid.org/COVID-19/ESID-COVID-19-Statement-March-2022>(Last accessed: May 23, 2024) available at.
15. Evans RA, Dube S, Lu Y, et al. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. *Lancet Reg Health Eur.* 2023;35:100747. doi:10.1016/j.lanepe.2023.100747
16. Paris R. SARS-CoV-2 infection and response to COVID-19 vaccination in patients with primary immunodeficiencies. *J Infect Dis.* 2023;228:S24-S33. doi:10.1093/infdis/jiad145
17. Shields AM, Faustini SE, Hill HJ, et al. SARS-CoV-2 vaccine responses in individuals with antibody deficiency: findings from the COV-AD study. *J Clin Immunol.* 2022;42:923-934. doi:10.1007/s10875-022-01231-7
18. Nourizadeh M, Feizabadi E, Mirmoghtadaei M, et al. Antibody production after COVID-19 vaccination in patients with inborn errors of immunity. *Iran J Immunol.* 2023;20:400-409. doi:10.22034/iji.2023.97759.2525
19. From The Medical Letter on Drugs and Therapeutics. Tixagevimab and Cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19. *JAMA.* 2022;327:384-385. doi:10.1001/jama.2021.24931
20. Mahase E. Covid-19: monoclonal antibody treatment to be rolled out to hospital patients with no antibody response. *BMJ.* 2021;374:n2319. doi:10.1136/bmj.n2319
21. Wang Q, Iketani S, Li Z, et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. *Cell.* 2023;186:279-286.e8. doi:10.1016/j.cell.2022.12.018.
22. National Institutes of Health (NIH). 2024;COVID-19 Treatment Guidelines Panel. Accessed May 23, 2023. <https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treatmentguidelines.pdf>
23. Casadevall A, Sullivan DJ. Late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial. *J Infect Dis.* 2024;229(2):617-618. doi:10.1093/infdis/jiad509
24. Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. *N Engl J Med.* 2021;384:610-618. doi:10.1056/NEJMoa2033700
25. Nurmi V, Knight C, Estcourt L, et al. The relationship between SARS-CoV-2 neutralizing antibody titers and avidity in plasma collected

- from convalescent nonvaccinated and vaccinated blood donors. *J Infect Dis.* 2023;228:245-250. doi:10.1093/infdis/jiad070
26. Cousins K, Sano K, Lam B, et al. Detection of SARS-CoV-2 antibodies in immunoglobulin products. *J Allergy Clin Immunol Pract.* 2023;11:2534-2541.e2. doi:10.1016/j.jaip.2023.05.005.
27. Hartmann J, Klein HG. Supply and demand for plasma-derived medicinal products - A critical reassessment amid the COVID-19 pandemic. *Transfusion.* 2020;60:2748-2752. doi:10.1111/trf.16078
28. Ma KC, Shirk P, Lambrou AS, et al. Genomic surveillance for SARS-CoV-2 variants: circulation of omicron lineages - United States, January 2022-May 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72:651-656. doi:10.15585/mmwr.mm7224a2
29. McIntosh D, Burnouf T, Karbiener M, Farcet MR, Kreil TR. Prevention and treatment of COVID-19 by mono- and poly-clonal antibodies. *Blood Transfus.* 2023;21:375-377. doi:10.2450/BloodTransfus.436
30. Wang X, Yuen TTT, Dou Y, et al. Vaccine-induced protection against SARS-CoV-2 requires IFN- γ -driven cellular immune response. *Nat Commun.* 2023;14:3440. doi:10.1038/s41467-023-39096-y
31. Li D, Xu M, Hooper AT, et al. Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles. *Sci Rep.* 2023;13:12784. doi:10.1038/s41598-023-39681-7

How to cite this article: Karbiener M, Kindle G, Meyts I, et al. Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency. *J Med Virol.* 2024;96:e29738. doi:10.1002/jmv.29738